Company: DRTSW
Filing Date: 2025-04-28
Form Type: 424B5
Source: 0001213900-25-035799
Chunk: 15

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 424B5
Chunk 15
---
 change their opinion
of our shares, our share price would likely decline. If one or more of these analysts cease coverage of our Company or fail to regularly
publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.

Sales of a substantial number of our ordinary shares in the public market, or the perception that they may occur, could cause the price of our ordinary shares to fall.

The market price of our ordinary shares could decline as a result of
sales of a large number of our ordinary shares in the public market following this offering. A substantial majority of our outstanding
ordinary shares are freely tradeable without restriction or further registration under the Securities Act of 1933, as amended (the “Securities
Act”). Volatility or a reduction in the market price of our ordinary shares could have an adverse effect on the market price of
the shares and existing warrants. The perception that these sales might occur may also cause the market price of our ordinary shares to
decline.

<div align='center'>S-7</div>

Because we do not anticipate paying any cash dividends on our ordinary shares in the foreseeable future, capital appreciation, if any, will be your sole source of gain.

We have never declared or paid cash dividends
on our ordinary shares. We anticipate that we will retain our earnings, if any, for future growth and therefore do not anticipate paying
cash dividends in the future. As a result, only appreciation of the price of our ordinary shares will provide a return to shareholders.

Purchasers of shares in this offering will experience immediate and substantial dilution in the book value of their investment.

The offering price per share is substantially higher than the as adjusted
net tangible book value per ordinary share before giving effect to this offering. Therefore, if you purchase shares in this offering,
you will pay a price per share that substantially exceeds the as adjusted net tangible book value per share after the completion of this
offering. Based on the offering price of $2.612 per share, you will experience immediate dilution of $1.44 per share, representing the
difference between our as adjusted net tangible book value per share as of December 31, 2024 and the offering price per share. See the
section titled “Dilution” for a more detailed description of the dilution to the Investor in the offering.

You may experience future dilution as a result of future equity offerings.

In order to raise additional capital, we expect
to